JP2003515323A5 - - Google Patents

Download PDF

Info

Publication number
JP2003515323A5
JP2003515323A5 JP2001538975A JP2001538975A JP2003515323A5 JP 2003515323 A5 JP2003515323 A5 JP 2003515323A5 JP 2001538975 A JP2001538975 A JP 2001538975A JP 2001538975 A JP2001538975 A JP 2001538975A JP 2003515323 A5 JP2003515323 A5 JP 2003515323A5
Authority
JP
Japan
Prior art keywords
canine
polypeptide
seq
fragment
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001538975A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003515323A (ja
Filing date
Publication date
Priority claimed from PCT/GB1999/003859 external-priority patent/WO2000029428A2/en
Priority claimed from GB0003527A external-priority patent/GB0003527D0/en
Priority claimed from GB0005071A external-priority patent/GB0005071D0/en
Application filed filed Critical
Priority claimed from PCT/GB2000/004317 external-priority patent/WO2001036486A2/en
Publication of JP2003515323A publication Critical patent/JP2003515323A/ja
Publication of JP2003515323A5 publication Critical patent/JP2003515323A5/ja
Pending legal-status Critical Current

Links

JP2001538975A 1999-11-18 2000-11-13 抗 体 Pending JP2003515323A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB99/03859 1999-11-18
PCT/GB1999/003859 WO2000029428A2 (en) 1998-11-18 1999-11-18 5t4 tumour-associated antigen for use in tumour immunotherapy
GB0003527A GB0003527D0 (en) 2000-02-15 2000-02-15 Antibodies
GB0003527.9 2000-02-15
GB0005071.6 2000-03-02
GB0005071A GB0005071D0 (en) 2000-03-02 2000-03-02 Antibodies
PCT/GB2000/004317 WO2001036486A2 (en) 1999-11-18 2000-11-13 Scfv antibodies against disease associated molecules

Publications (2)

Publication Number Publication Date
JP2003515323A JP2003515323A (ja) 2003-05-07
JP2003515323A5 true JP2003515323A5 (cg-RX-API-DMAC7.html) 2007-12-20

Family

ID=27255534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001538975A Pending JP2003515323A (ja) 1999-11-18 2000-11-13 抗 体

Country Status (7)

Country Link
US (4) US7074909B2 (cg-RX-API-DMAC7.html)
EP (1) EP1242456B1 (cg-RX-API-DMAC7.html)
JP (1) JP2003515323A (cg-RX-API-DMAC7.html)
CN (1) CN1423660A (cg-RX-API-DMAC7.html)
AU (1) AU1290001A (cg-RX-API-DMAC7.html)
CA (1) CA2391925A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001036486A2 (cg-RX-API-DMAC7.html)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276488B2 (en) 1997-06-04 2007-10-02 Oxford Biomedica (Uk) Limited Vector system
US7635687B2 (en) * 1997-06-04 2009-12-22 Oxford Biomedica (Uk) Limited Vector system
WO1998055607A2 (en) 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
JP2003515323A (ja) * 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
US7402666B2 (en) 2000-11-13 2008-07-22 Oxford Biomedica (Uk) Ltd. Nucleotide encoding canine 5T4 antigen
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
GB0126378D0 (en) * 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
AU2003259913A1 (en) * 2002-08-19 2004-03-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
TW200530269A (en) 2003-12-12 2005-09-16 Chugai Pharmaceutical Co Ltd Anti-Mpl antibodies
CA2573656A1 (en) * 2004-07-13 2006-02-16 Cell Genesys, Inc. Aav vector compositions and methods for enhanced expression of immunoglobulins using the same
TW200616662A (en) * 2004-09-10 2006-06-01 Wyeth Corp Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates
WO2006106903A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2構造異性体
EP3623473A1 (en) 2005-03-31 2020-03-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
US9241994B2 (en) 2005-06-10 2016-01-26 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical compositions containing sc(Fv)2
CA2610987C (en) 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
WO2006132352A1 (ja) * 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2を含有する医薬組成物
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
EP2009101B1 (en) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
KR20090069330A (ko) 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
US8097422B2 (en) 2007-06-20 2012-01-17 Salk Institute For Biological Studies Kir channel modulators
KR100949791B1 (ko) * 2007-12-18 2010-03-30 이동기 오프-타겟 효과를 최소화하고 ＲＮＡｉ 기구를 포화시키지않는 신규한 ｓｉＲＮＡ 구조 및 그 용도
EP2313784B1 (en) * 2008-07-15 2015-02-18 Oxford BioMedica (UK) Limited Immunotherapeutic method
WO2010087994A2 (en) 2009-01-30 2010-08-05 Whitehead Institute For Biomedical Research Methods for ligation and uses thereof
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
CA2846432A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
BR112014018192A8 (pt) 2012-01-24 2021-03-02 Epic Sciences Inc método e kit para detecção de células tumorais circulantes 5t4-positivas, bem como métodos de diagnóstico de câncer 5t4-positivo e de seleção para atividade e eficácia de conjugado fármaco-anticorpo para tratamento de câncer
US20160304617A1 (en) 2013-06-17 2016-10-20 Asana Biosciences, Llc 5t4-targeted immunofusion molecule and methods
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
CN105813655B (zh) 2013-10-11 2022-03-15 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
CN105979970B (zh) 2013-10-11 2019-09-10 梅尔莎纳医疗公司 蛋白质-聚合物-药物共轭物
JPWO2015133484A1 (ja) * 2014-03-04 2017-04-06 国立大学法人徳島大学 腎臓疾患に関するマーカー及びその利用
WO2016120331A1 (de) 2015-01-28 2016-08-04 Karl Sebastian Lang Agonistische anti-cd66cd66 antikörper für die antiviralen therapie
BR112018009312A8 (pt) 2015-12-28 2019-02-26 Chugai Pharmaceutical Co Ltd método para promover eficiência de purificação de polipeptídeo contendo região de fc
CN106749656B (zh) * 2016-11-11 2018-04-13 郑州师范学院 一种抗小鼠RCN3蛋白单克隆ScFv抗体及其淘选方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
KR102609624B1 (ko) 2017-03-15 2023-12-05 옥스포드 바이오메디카(유케이) 리미티드 방법
CA3080429A1 (en) 2017-11-01 2019-05-09 Nantbio, Inc. Il8 blocking emt pathway and overcoming cancer stem cells
US11638760B2 (en) 2017-11-27 2023-05-02 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
EP3727463A1 (en) 2017-12-21 2020-10-28 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN120795158A (zh) 2018-03-12 2025-10-17 健玛保 抗体
CA3117050A1 (en) 2018-10-29 2020-05-07 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
AU2024238898A1 (en) 2023-03-22 2025-10-16 Salubris Biotherapeutics, Inc. Anti-5t4 antigen binding domains, antibody-drug conjugates and methods of use thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481051A (en) * 1969-02-06 1969-12-02 Paramount Packaging Corp Heating apparatus
US4009778A (en) * 1975-11-04 1977-03-01 The Kartridg Pak Co. Dual compartment package and method for making same
US4267768A (en) * 1976-09-20 1981-05-19 David M. Cieslak Process for fabricating a reclosable bag
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
EP0336562B1 (en) * 1988-03-04 1995-06-14 Cancer Research Campaign Technology Ltd. Improvements relating to antigens
US5591624A (en) * 1988-03-21 1997-01-07 Chiron Viagene, Inc. Retroviral packaging cell lines
US5060146A (en) 1988-04-08 1991-10-22 International Business Machines Corporation Multilingual indexing system for alphabetical lysorting by comparing character weights and ascii codes
JPH04500308A (ja) 1989-05-17 1992-01-23 リサーチ・コーポレーション・テクノロジーズ・インコーポレーテッド 組換え型生成物のレトロウィルス媒介分泌
GB9109645D0 (en) 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
GB9223816D0 (en) 1992-11-13 1993-01-06 Medical Res Council Heat shock proteins and the treatment of tumours
EP0621338A3 (en) * 1993-04-21 1997-10-29 Ajinomoto Kk The interleukin-2 response blocking immunosuppressor.
CA2162689C (en) * 1993-05-12 2000-07-18 Marc D. Better Immunotoxins comprising gelonin and an antibody
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
DE69523857T2 (de) * 1994-09-16 2002-06-13 Merck Patent Gmbh Immunokonjugate
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US5824762A (en) * 1994-11-28 1998-10-20 Dow Corning Toray Silicone Co., Ltd. Organopolysiloxane and method for the preparation of the same
WO1996030504A1 (en) 1995-03-24 1996-10-03 Genetic Therapy, Inc. Modified viral envelope polypeptide
FR2732348B1 (fr) 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Systeme d'expression conditionnel
US5637462A (en) * 1995-04-19 1997-06-10 Incyte Pharmaceuticals, Inc. Cathepsin C homolog
US20030026789A1 (en) 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
EP0833948B1 (en) * 1995-06-06 2005-12-21 Human Genome Sciences, Inc. Colon specific gene and protein
DE19531346A1 (de) * 1995-08-25 1997-02-27 Gsf Forschungszentrum Umwelt Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen
WO1997017090A1 (en) 1995-11-07 1997-05-15 Baylor College Of Medicine Adenovirus-mediated production of bioactive proteins by mammalian cells and animals
SE9601245D0 (sv) * 1996-03-29 1996-03-29 Pharmacia Ab Chimeric superantigens and their use
TW517061B (en) 1996-03-29 2003-01-11 Pharmacia & Amp Upjohn Ab Modified/chimeric superantigens and their use
CZ353698A3 (cs) * 1996-05-04 1999-02-17 Zeneca Limited Monoklonální protilátka proti CEA, konjugáty, které ji obsahují, způsob jejich přípravy a farmaceutický přípravek, který je obsahuje
JP4175678B2 (ja) * 1996-06-07 2008-11-05 武田薬品工業株式会社 新規ペプチド、その製造法および用途
WO1998012227A1 (en) * 1996-09-19 1998-03-26 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6348584B1 (en) * 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
WO1998055607A2 (en) * 1997-06-04 1998-12-10 Oxford Biomedica (Uk) Limited Tumor targeted vector
JPH1156368A (ja) * 1997-08-27 1999-03-02 Nippon Seibutsu Kagaku Kenkyusho 猫トロンボポエチンの活性を有する因子
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強
EP1160323A1 (en) * 1998-11-18 2001-12-05 Oxford Biomedica (UK) Limited 5T4 tumour-associated antigen for use in tumour immunotherapy
EP2161286A1 (en) * 1999-11-18 2010-03-10 Oxford Biomedica (UK) Limited Antibodies
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体

Similar Documents

Publication Publication Date Title
JP2003515323A5 (cg-RX-API-DMAC7.html)
WO2005051998A3 (en) Antibodies binding to a c-terminal fragment of apolipoprotein e
IL163066A (en) Ligands for the zcytor17 receptor
JP2006516189A5 (cg-RX-API-DMAC7.html)
JP2006516098A5 (cg-RX-API-DMAC7.html)
JP2002524024A5 (cg-RX-API-DMAC7.html)
JP2002519061A5 (cg-RX-API-DMAC7.html)
JP2002537791A5 (cg-RX-API-DMAC7.html)
JP2002535956A5 (cg-RX-API-DMAC7.html)
JP2002505841A5 (cg-RX-API-DMAC7.html)
WO2004035618A3 (en) Nucleic acids coding for adhesion factor of group b streptococcus, adhesion factors of group b streptococcus and further uses thereof
WO2005087811A3 (en) Estrogen receptors and methods of use
JP2002517193A5 (cg-RX-API-DMAC7.html)
JP2002540769A5 (cg-RX-API-DMAC7.html)
JP2006527990A5 (cg-RX-API-DMAC7.html)
ATE414156T1 (de) Lipase-varianten
WO2001053347A3 (fr) Gene nphs2 implique dans le syndrome nephrotique cortico-resistant, proteine codee par ce gene et utilisations diagnostiques et therapeutiques
JP2006515984A5 (cg-RX-API-DMAC7.html)
WO2003022039A1 (fr) Procede permettant de conferer une resistance a un virus au moyen d'une proteine vegetale se liant a une proteine de transport de virus vegetal
JPH10210974A5 (cg-RX-API-DMAC7.html)
WO2006090090A3 (fr) Epitopes de vih et composition pharmaceutique les contenant
WO2007058267A8 (ja) 新規タンパク質及びそれをコードする遺伝子
WO2001070808A3 (en) Angiogenesis - associated proteins, and nucleic acids encoding the same
JP2004500829A5 (cg-RX-API-DMAC7.html)
NO20011961D0 (no) PRV-1-genet og anvendelsen av dette